Search research articles
Contact Us
Filters
Showing results (431-440 of 869) with videos related to
Page
of 87
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
Klaus Podar, Giovanni Tonon, Martin Sattler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 3, 2013
Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration
Sergio Giralt, Philip L McCarthy, Kenneth C Anderson, et al.
Blood
|
January 30, 2010
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia
Aldo M Roccaro, Antonio Sacco, Monette Aujay, et al.
British Journal of Haematology
|
September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
Klaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine
|
August 7, 2024
Exploring the anti-myeloma potential of composite nanoparticles As<sub>4</sub>S<sub>4</sub>/Fe<sub>3</sub>O<sub>4</sub>: Insights from in vitro, ex vivo and in vivo studies
Danka Cholujova, Zdenka Lukacova Bujnakova, Erika Dutkova, et al.
JAMA Oncology
|
September 16, 2016
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis
Nikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, et al.
American Journal of Hematology
|
January 6, 2015
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study
María Victoria Mateos, Paul G Richardson, Meletios A Dimopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2005
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma
Pierfrancesco Tassone, Paola Neri, Renate Burger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2013
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth
Emanuela Leone, Eugenio Morelli, Maria T Di Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2012
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma
Andrzej J Jakubowiak, Don M Benson, William Bensinger, et al.
Page
of 87
Search research articles
Search
Showing results (431-440 of 869) with videos related to
Sort By:
Page
of 87
Proceedings of the National Academy of Sciences of the United States of America
|
December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
Klaus Podar, Giovanni Tonon, Martin Sattler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 3, 2013
Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration
Sergio Giralt, Philip L McCarthy, Kenneth C Anderson, et al.
Blood
|
January 30, 2010
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia
Aldo M Roccaro, Antonio Sacco, Monette Aujay, et al.
British Journal of Haematology
|
September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
Klaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine
|
August 7, 2024
Exploring the anti-myeloma potential of composite nanoparticles As<sub>4</sub>S<sub>4</sub>/Fe<sub>3</sub>O<sub>4</sub>: Insights from in vitro, ex vivo and in vivo studies
Danka Cholujova, Zdenka Lukacova Bujnakova, Erika Dutkova, et al.
JAMA Oncology
|
September 16, 2016
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis
Nikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, et al.
American Journal of Hematology
|
January 6, 2015
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study
María Victoria Mateos, Paul G Richardson, Meletios A Dimopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2005
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma
Pierfrancesco Tassone, Paola Neri, Renate Burger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2013
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth
Emanuela Leone, Eugenio Morelli, Maria T Di Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2012
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma
Andrzej J Jakubowiak, Don M Benson, William Bensinger, et al.
Page
of 87